Life Science News

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD and TSX: VMD.TO), a home medical equipment supplier and the nation's largest independent provider of ventilation that provides post-acute respiratory care services, today reported its financial results for the three and nine months ended September 30, 2021.

Operational highlights (all dollar amounts are USD):

  • Total net revenues for the current quarter were $29.3 million and included $1.5 million of net revenues for contact and vaccine tracing services and product sales related to the COVID-19 pandemic. Net revenues attributable to the Company's core business for the quarter ended September 30, 2021 were $27.8 million, a new Company record, and an increase of $2.9 million, or 12%, over core business revenues reported for the comparable quarter ended September 30, 2020. Net revenues attributable to the core business were up approximately 6% from the second quarter of 2021.

  • Net income for the quarter ended September 30, 2021 totaled $1.8 million, compared to $2.8 million for the quarter ended September 30, 2020. Net income for the nine months ended September 30, 2021 totaled $5.0 million, compared to $26.5 million for the nine months ended September 30, 2020. In the prior year comparable period, net income included an income tax benefit of $5.3 million and $29.3 million of COVID-19 response sales and services during the height of the COVID-19 pandemic.

  • Adjusted EBITDA for the quarter ended September 30, 2021 totaled $7.4 million and Adjusted EBITDA for the nine months ended September 30, 2021 totaled $19.7 million. A reconciliation of reported non-GAAP financial measures to their most directly comparable U.S. GAAP financial measures can be found in the tables accompanying this press release.

  • The Company had a cash balance of $26.9 million at September 30, 2021 ($31.0 million at December 31, 2020) and an overall working capital balance of $27.2 million at September 30, 2021 ($24.2 million at December 31, 2020). Long-term debt as of September 30, 2021 was $4.3 million ($5.8 million at December 31, 2020).

  • The Company grew its ventilator patient count to 8,200 at September 30, 2021, compared to 8,103 at June 30, 2021.

  • The Company expects to generate net revenues attributable to its core business of approximately $27.8 million to $28.8 million during the fourth quarter of 2021. While the Company's COVID-19 response related business has slowed during the current year, the Company is continuing to pursue additional sales and support revenues and estimates fourth quarter 2021 net revenues of approximately $1.5 million to $1.7 million related to the COVID-19 pandemic. Total net revenues for the fourth quarter of 2021 are estimated to be approximately $29.3 million to $30.5 million.

"We are excited to report another record breaking quarter despite headwinds associated with the Delta variant," said Casey Hoyt, Viemed's CEO. "The resiliency of our workforce and the strength of our relationships has driven our continued growth during these unprecedented times. The nationwide sales training programs conducted during the previous quarters have concluded and are expected to give our sales force new products to add to our superior service model. As we look forward, we continue to believe that our ability to provide technology enabled healthcare in the home setting will create enormous value and positive patient outcomes."

Conference Call Details

The Company will host a conference call to discuss second quarter results on Tuesday, November 2, 2021 at 11:00 a.m. ET.

The call-in numbers for participants are:

US Toll Free Dial In: 1-877-407-0784
International Toll Free Dial In: 1-201-689-8560
Meeting ID Number: 13723389
Live Event Call me™ Link (Available 15 minutes prior to start time for participant entry)

Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company's website.


Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed's service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Visit our website at

For further information, please contact:

Glen Akselrod
Bristol Capital

Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "potential", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", or "projects", or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results "will", "should", "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's net revenue guidance for the fourth quarter, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; the impact of the COVID-19 pandemic and the actions taken by governmental authorities, individuals and companies in response to the pandemic on our business, financial condition and results of operations, including on the Company's patient base, revenues, employees, and equipment and supplies; significant capital requirements and operating risks that the Company may be subject to; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of the Company's common shares; the Company's novel business model; the risk that the clinical application of treatments that demonstrate positive results in a study may not be positively replicated or that such test results may not be predictive of actual treatment results or may not result in the adoption of such treatments by providers; the state of the capital markets; the availability of funds and resources to pursue operations; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers and the recall of certain Royal Philips BiPAP and CPAP devices and ventilators that we distribute and sell; granting of permits and licenses in a highly regulated business; competition; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company's status as an emerging growth company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, such as the COVID-19 pandemic, and claims resulting from such events or concerns; as well as those risk factors discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at, including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and with the securities regulatory authorities in certain provinces of Canada available at Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

(Expressed in thousands of U.S. Dollars, except share amounts)

September 30, 2021
December 31, 2020
Current assets
Cash and cash equivalents $ 26,867 $ 30,981
Accounts receivable, net of allowance for doubtful accounts of $7,115 and $9,013 at September 30, 2021 and December 31, 2020, respectively 12,696 12,373
Inventory, net of inventory reserve of $1,237 and $1,353 at September 30, 2021 and December 31, 2020, respectively 2,622 2,310
Income tax receivable 1,420
Prepaid expenses and other assets 3,761 1,511
Total current assets $ 47,366 $ 47,175
Long-term assets
Property and equipment, net 59,036 55,056
Equity investments 1,942 733
Deferred tax asset 6,281 8,733
Other long-term assets 861 863
Total long-term assets $ 68,120 $ 65,385
TOTAL ASSETS $ 115,486 $ 112,560
Current liabilities
Trade payables $ 4,734 $ 2,096
Deferred revenue 3,795 3,409
Income taxes payable 340
Accrued liabilities 9,283 12,595
Current portion of lease liabilities 481 2,741
Current portion of long-term debt 1,906 1,836
Total current liabilities $ 20,199 $ 23,017
Long-term liabilities
Accrued liabilities 730 1,292
Long-term lease liabilities 834 762
Long-term debt 4,347 5,796
Total long-term liabilities $ 5,911 $ 7,850
TOTAL LIABILITIES $ 26,110 $ 30,867
Commitments and Contingencies
Common stock - No par value: unlimited authorized; 39,630,446 and 39,185,182 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 13,957 9,181
Additional paid-in capital 6,501 7,320
Accumulated other comprehensive loss (330 ) (451 )
Retained earnings 69,248 65,643

(Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)

Three Months Ended
September 30,
Nine Months Ended
September 30,
2021 2020 2021 2020
Revenue $ 29,285 $ 33,447 $ 85,100 $ 100,107
Cost of revenue 10,904 13,994 31,352 39,174
Gross profit $ 18,381 $ 19,453 $ 53,748 $ 60,933
Operating expenses
Selling, general and administrative 13,260 13,550 40,653 40,555
Research and development 576 243 1,498 688
Stock-based compensation 1,302 1,234 3,845 3,581
Depreciation 211 202 618 612
Loss (gain) on disposal of property and equipment 145 203 304 (2,424 )
Other expense (income) (32 ) (19 ) (85 ) (3,593 )
Income from operations $ 2,919 $ 4,040 $ 6,915 $ 21,514
Non-operating income and expenses
Income from equity method investments (331 ) (21 ) (782 ) (36 )
Interest expense, net of interest income 75 116 249 409
Net income before taxes 3,175 3,945 7,448 21,141
Provision (benefit) for income taxes 1,386 1,141 2,409 (5,318 )
Net income $ 1,789 $ 2,804 $ 5,039 $ 26,459
Other comprehensive income (loss)
Change in unrealized gain/loss on derivative instruments, net of tax 21 24 121 (321 )
Other comprehensive income (loss) $ 21 $ 24 $ 121 $ (321 )
Comprehensive income $ 1,810 $ 2,828 $ 5,160 $ 26,138
Net income per share
Basic $ 0.05 $ 0.07 $ 0.13 $ 0.69
Diluted $ 0.04 $ 0.07 $ 0.12 $ 0.66
Weighted average number of common shares outstanding:
Basic 39,607,540 39,107,640 39,442,088 38,603,267
Diluted 40,659,353 41,155,668 40,716,747 40,377,608

(Expressed in thousands of U.S. Dollars)

Nine Months Ended September 30,
2021 2020
Cash flows from operating activities
Net income $ 5,039 $ 26,459
Adjustments for:
Depreciation 8,192 6,745
Change in allowance for doubtful accounts 5,250 7,031
Change in inventory reserve (116 )
Share-based compensation 3,845 3,581
Distributions of earnings received from equity method investments 172
Income from equity method investments (782 ) (36 )
Loss (gain) on disposal of property and equipment 304 (2,424 )
Deferred income tax expense (benefit) 2,410 (7,593 )
Net change in working capital
Increase in accounts receivable (5,573 ) (6,986 )
Increase in inventory (196 ) (1,402 )
Increase in prepaid expenses and other assets (2,259 ) (1,771 )
Increase in trade payables 2,638 2,739
Increase in deferred revenue 386 297
(Decrease) increase in accrued liabilities (3,711 ) 2,397
Change in income tax payable/receivable (1,760 ) 282
Net cash provided by operating activities $ 13,839 $ 29,319
Cash flows from investing activities
Purchase of property and equipment (13,080 ) (8,204 )
Investment in equity investments (599 ) (30 )
Proceeds from sale of property and equipment 496 5,187
Net cash used in investing activities $ (13,183 ) $ (3,047 )
Cash flows from financing activities
Proceeds from exercise of options 112 1,780
Principal payments on notes payable (113 ) (104 )
Principal payments on term note (1,255 ) (1,199 )
Shares redeemed to pay income tax (1,434 )
Repayments of lease liabilities (2,080 ) (7,708 )
Net cash used in financing activities $ (4,770 ) $ (7,231 )
Net (decrease) increase in cash and cash equivalents (4,114 ) 19,041
Cash and cash equivalents at beginning of year 30,981 13,355
Cash and cash equivalents at end of period $ 26,867 $ 32,396
Supplemental disclosures of cash flow information
Cash paid during the period for interest $ 278 $ 437
Cash paid during the period for income taxes, net of refunds received $ 1,760 $ 1,975
Supplemental disclosures of non-cash transactions
Net non-cash changes to finance lease balances $ 42 $ 3,002
Net non-cash changes to operating lease balances $ 372 $ 57

Non-GAAP Financial Measures

This press release refers to "Adjusted EBITDA" which is a non-GAAP financial measure that does not have a standardized meaning prescribed by U.S. GAAP. The Company's presentation of this financial measure may not be comparable to similarly titled measures used by other companies. Adjusted EBITDA is defined as net income (loss) before interest expense, income tax expense (benefit), depreciation and amortization, and stock-based compensation. Management believes Adjusted EBITDA provides helpful information with respect to the Company's operating performance as viewed by management, including a view of the Company's business that is not dependent on the impact of the Company's capitalization structure and items that are not part of the Company's day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company's operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company's employees, (iii) for planning purposes, including the preparation of the Company's internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company's operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company's operating performance in the same manner as management. The following table is a reconciliation of net income (loss), the most directly comparable U.S. GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:

Reconciliation of Net Income to Non-GAAP Adjusted EBITDA
(Expressed in thousands of U.S. Dollars)

For the quarter ended September
30, 2021
June 30,
March 31,
31, 2020
30, 2020
June 30,
March 31,
31, 2019
Net Income $ 1,789 $ 1,566 $ 1,684 $ 5,071 $ 2,804 $ 19,412 $ 4,243 $ 2,388
Add back:
Depreciation 2,867 2,716 2,609 2,835 2,425 2,190 2,130 2,003
Interest expense 75 83 91 100 116 135 158 212
Stock-based compensation 1,302 1,236 1,307 1,301 1,234 1,196 1,151 908
Income tax expense (benefit) 1,386 1,246 (223 ) 151 1,141 (6,646 ) 187 58
Adjusted EBITDA $ 7,419 $ 6,847 $ 5,468 $ 9,458 $ 7,720 $ 16,287 $ 7,869 $ 5,569

Three Months Ended
September 30, 2021
Nine Months Ended
September 30, 2021
Net Income $ 1,789 $ 5,039
Add back:
Depreciation 2,867 8,192
Interest expense 75 249
Stock-based compensation 1,302 3,845
Income tax expense 1,386 2,409
Adjusted EBITDA $ 7,419 $ 19,734

Use of Non-GAAP Financial Measures

Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. It is not a measurement of the Company's financial performance under U.S. GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with U.S. GAAP and may not be comparable to other similarly titled measures of other businesses. Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of the Company's operating results as reported under U.S. GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters the Company considers not to be indicative of ongoing operations; and other companies in the Company's industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.

Key Financial and Operational Information
(Expressed in thousands of U.S. Dollars, except vent patients)

For the quarter ended September
30, 2021
June 30,
March 31,
31, 2020
30, 2020
June 30,
March 31,
31, 2019
Financial Information:
Revenue $ 29,285 $ 27,399 $ 28,416 $ 31,202 $ 33,447 $ 42,854 $ 23,806 $ 21,448
Gross Profit $ 18,381 $ 17,625 $ 17,742 $ 19,178 $ 19,453 $ 25,927 $ 15,553 $ 14,243
Gross Profit % 63 % 64 % 62 % 61 % 58 % 61 % 65 % 66 %
Net Income $ 1,789 $ 1,566 $ 1,684 $ 5,071 $ 2,804 $ 19,412 $ 4,243 $ 2,388,000
Cash (As of) $ 26,867 $ 31,151 $ 31,097 $ 30,981 $ 32,396 $ 29,707 $ 8,409 $ 13,355
Total Assets (As of) $ 115,486 $ 111,014 $ 113,001 $ 112,560 $ 113,969 $ 112,178 $ 86,801 $ 82,596
Adjusted EBITDA (1) $ 7,419 $ 6,847 $ 5,468 $ 9,458 $ 7,720 $ 16,287 $ 7,869 $ 5,569,000
Operational Information:
Vent Patients (2) 8,200 8,103 7,733 7,892 7,788 7,705 7,965 7,759

(1) Refer to "Non-GAAP Financial Measures" section above for definition of Adjusted EBITDA.

(2) Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

How Do Medical Devices Get Approved?

How Do Medical Devices Get Approved?

Life science investors are familiar with the arduous path new drugs must go through to reach the market. But how do medical devices get approved?

In terms of devices, the same rigorous testing and inspection are required from regulatory agencies. The US Food and Drug Administration (FDA) is the agency tasked with reviewing new devices and making amendments to already approved devices.

More specifically, medical device approval is done through the FDA’s Center for Devices and Radiological Health (CDRH). The CDRH looks after the entire regulation process for companies that manufacture, repackage, relabel and import devices to the US.

Keep reading...Show less

Danaher Announces Appointment of Feroz Dewan to Danaher Board

Danaher Corporation (NYSE: DHR) announced today that it has appointed Feroz Dewan to its Board of Directors and to the Board's Science & Technology Committee. This addition expands the size of Danaher's Board from thirteen to fourteen members.

Mr. Dewan is currently CEO of Arena Holdings Management, a global investment business. From 2003 to 2015, he worked at Tiger Global Management, most recently as Head of Public Equities. Prior to that, Mr. Dewan was a private equity investor at Silver Lake Partners.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Abbott Hosts Conference Call for Second-Quarter Earnings

Abbott (NYSE: ABT) will announce its second-quarter 2022 financial results on Wednesday, July 20, 2022 before the market opens.

The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at . An archived edition of the call will be available later that day.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
ALR Technologies Completes Definitive Manufacturing Agreement with Infinovo Medical for the GluCurve Pet CGM Hardware

ALR Technologies Completes Definitive Manufacturing Agreement with Infinovo Medical for the GluCurve Pet CGM Hardware

ALR Technologies SG Pte. Ltd ("ALRT" or the "Company") (OTCQB: ALRT), the diabetes management company, announces the completion of a definitive manufacturing agreement with Infinovo Medical Co. Ltd ("Infinovo") to manufacture and supply the Continuous Glucose Monitor ("CGM") hardware that will be utilized as part of the ALRT GluCurve Pet CGM (the "Manufacturing Agreement"). The Manufacturing Agreement gives ALRT the exclusive global rights to distribute the Infinovo CGM hardware for the animal health market, providing long-term production and supply. Subject to the satisfaction of all closing conditions it is expected that initial deliveries of product by Infinovo will be made during Q4 of 2022

"Executing the Manufacturing Agreement with Infinovo marks another major milestone in our path to commercialization and profitability," comments Sidney Chan, Chairman and CEO of ALRT. "Our next targeted milestone is securing distribution for the ALRT GluCurve Pet CGM. We have been working with many of the largest global distributors and pharmaceutical companies in animal health, evaluating different distribution opportunities ranging from joint venture partnerships to sales and distribution agreements. We believe we have narrowed in on the right company and right deal structure to best bring value to our shareholders and to those who care for diabetic pets. We hope to announce the details of this pivotal next step in the near future."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Bloom Health Partners CEO Andrew Morton

Bloom Health Partners CEO Andrew Morton: We're Executing the Plan That We Promised Investors

Bloom Health Partners CEO Andrew Morton: We're Executing The Plan That We Promised

Keep reading...Show less

Medtronic Board appoints Lidia Fonseca as a new director

Medtronic plc (NYSE: MDT) today announced that its Board of Directors appointed Lidia Fonseca Executive Vice President, Chief Digital and Technology Officer at Pfizer, to the Board as an independent director, effective June 27, 2022 . Ms. Fonseca will serve on the Compensation Committee and Science and Technology Committee of the Board.

"We are thrilled to welcome Lidia to Medtronic's Board of Directors," said Geoff Martha , Medtronic chairman and chief executive officer. "She has an impressive history of developing digital healthcare solutions that deliver powerful insights to improve patients' lives. Her extensive knowledge and expertise will provide the Board with an important dimension and a tremendously valuable perspective as we drive toward our bold ambition to become the global leader in healthcare technology."

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News